TrialMedical oncology (Northwood, London, England)2017

Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.

I Walter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.